Tim Murphy

Callen-Lorde’s program, with funding from the Keith Haring Foundation, lets NPs dive deeper into care for queer and trans people.

For now, with a few exceptions, treatment options run well into the thousands of dollars—but that may change in the years ahead.

Pharmacists don’t want to dispense PrEP unless they are reimbursed for it—plus, too many pharmacists and customers are uninformed about pharmacist-initiated PrEP.

These conversations contain valuable clues about how to better reach one of the populations that still has the highest rates of new HIV diagnoses in the U.S.

With few treatment breakthroughs coming soon for chronic neuropathic pain, people living with HIV are relying on a grab bag of tools—and one another—to manage a crushing foe.

City leaders who nearly outlawed needle exchange say it was disrupting a Black neighborhood, but one nonprofit says that CDC-approved, lifesaving work has been banned.

My Epidemic is about "one man's struggle as doctor, patient and survivor."

The first wave of HIV/AIDS doctors are letting go of their duties—if not always their patients. But the need for specialists is still high, especially in the South.

From a pop-up site in the heart of the Tenderloin to roving teams, San Francisco Community Health Center and GLIDE partnered to connect clients to care.

Helping my longtime friend Jeremy find such trials alerted me to this ongoing problem—which will only be reversed if patients, doctors, and trial reviewers keep pushing back on Pharma.

For the first time, the influential annual CROI was going to postpone making its ample data available to the public. But the global HIV community swiftly protested.

They say that the longtime HIV researcher already had a sketchy record that made him the perfect Trump flunky.